STAT

Opinion: All study participants have a right to know their own results. My lab has been doing that for years

Giving study participants their individual results can drive greater public participation in research, increased support for science, and better health.

For less than $100 and a sample of spit, you can learn about your genes, your disease susceptibility, and your ethnic heritage. Wearable sensors report on your sleep patterns, your heart rate, and what air pollutants are nearby. With Detox Me Action Kit, a crowdsourced project my team recently launched, you can find out what common hormone-disrupting chemicals are in your body, including ingredients that manufacturers don’t have to disclose. Then there’s all the data in your medical record that you can now get hold of, thanks to changes in health laws.

Between the rise in direct-to-consumer products and more transparent medical care, people today have access to myriad types of data about their personal health — and they’ve come to expect it. Yet for participants in most research studies, outdated ethical standards prevent them from learning anything at all about what was found in their blood, urine, or any other tissue they donated for research.

Thousands of Americans take part in studies and clinical trials every year to support work ranging from basic laboratory science to long-term epidemiological studies

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks